Counter
Safe Access          Sensible Use
The Los Angeles Patients & Caregivers Group
Since 2004 the LAPCG has
provided a community-
based solution for the need
to safe access to medicine
for patients suffering from
HIV/AIDS, cancer, multiple
sclerosis, chronic pain, and
other serious illness. LAPCG
is organized to serve legally
qualified patients in the
Greater Los Angeles area.    
7213 Santa Monica Blvd.
W. Hollywood, CA 90046
(323) 882-6033
Explore LAPCG's
MENU
Welcome to the
LOS ANGELES PATIENTS & CAREGIVERS GROUP

YES!
We are open!

Edibles Discount & Spin-the-Wheel on Sunday
Edibles are 10% off on Sunday. This is a great chance to try some non-
smoked options or to stock up on your favorites. You'll find Fran Cakes, Kind
Cookies, hard candies and more! All of our edible preparations are made by
your fellow members and carefully screened for efficacy and consistency.
Please let the staff know how they work for you.
You can also "
Spin the Wheel" on Sunday to win prizes.


AGl Holder Faces Tough ASA Questions
Congress Challenges Cannabis Scheduling, Enforcement
U.S. Attorney General Eric Holder faced tough questions about medical cannabis at a recent House
Judiciary Committee hearing, thanks to ASA's work with two of the committee members. Rep. Steve
Cohen (D, TN) and Rep. Jared Polis (D, CO) each pressed the AG on issues that affect medical
cannabis patients.

Rep. Cohen challenged Holder on the Department of Justice's approach to rescheduling cannabis to
make it available by prescription everywhere in the nation. Rep. Cohen asked Holder to respond to
the recent federal sentencing order in the case of California medical cannabis provider Charles C.
Lynch, quoting the judge's comments that Lynch was "caught in the middle of shifting positions" on
the medical use of cannabis, and that "much of the problems could be ameliorated…by the
reclassification of marijuana from Schedule I."

Holder responded without addressing the specifics of the Lynch case, but said that "so far as state
medical marijuana laws are concerned, we will not use federal resources to target medical marijuana
patients or their providers."

ASA had urged Rep. Cohen to ask this question because a rescheduling petition is currently waiting
for review by the Department of Justice.

Rep. Polis, one of the newest members of the House Judiciary Committee and another
representative with whom ASA worked closely on developing questions, then asked Holder to clarify
federal medical cannabis policy. After voicing his support for the DOJ memo discouraging US
Attorneys from prosecuting individuals in clear and unambiguous compliance with state law, Rep.
Polis asked the attorney general to "describe the objective processes DEA and US Attorneys are using
in order to make a determination about whether individuals are in 'clear and unambiguous'
compliance with state law."

Holder said that he expects U.S. Attorneys to evaluate on a case-by-case basis whether individuals
are acting "consistent with state law."

Rep. Polis replied that "the question of whether or not its consistent with state law be left to state
enforcement actions," and pressed Holder to clarify what steps he is taking to ensure that the policy
outlined in the memo is not undermined or contradicted by field agents, as happened recently in
Rep. Polis' district in Colorado.

The attorney general admitted that it is his responsibility "to make sure that what we've set out as
policy is being followed. To the extent DEA or US Attorneys are not following that policy, my
responsibility is to make sure the policy is clear, disseminated, and that employees of the Justice
Department act accordingly."

"We're grateful that medical cannabis patients now have strong allies in Congress, such as Reps.
Cohen and Polis," said ASA Government Affairs Director Caren Woodson after the hearing. "ASA has
worked hard to ensure that members with oversight over federal policy have all the information they
need to ask the tough questions and help formulate more sensible approaches to medical cannabis."